Class II · Moderate risk
Artesunate Lyophilized Powder for Injection
Penicillin Cross Contamination: Multiple finished products potentially contaminated with penicillin.
FDA Drug Recalls
14,806 recalls, newest first
Class II · Moderate risk
Meloxicam capsules
Penicillin Cross Contamination: Multiple finished products potentially contaminated with penicillin.
Class II · Moderate risk
Leucovorin Calcium capsules
Penicillin Cross Contamination: Multiple finished products potentially contaminated with penicillin.
Class II · Moderate risk
Bi-Est 80:20 Progesterone
Penicillin Cross Contamination: Multiple finished products potentially contaminated with penicillin.
Class I · High risk
Cytarabine Injection 100 mg/5 mL
Presence of Particulate Matter
Class I · High risk
Bupivacaine Hydrochloride Inj.
Presence of Particulate Matter: Presence of free-floating and embedded iron oxide particles.
Class II · Moderate risk
Ketorolac Trom 30 Mg/Ml Inj
Crystallization
Class II · Moderate risk
Captopril Tablets
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Captopril Tablets
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Captopril Tablets
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Zonisamide Capsules
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Zonisamide Capsules
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Metoprolol Succinate Extended-Release Tablets
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Metoprolol Succinate Extended-Release Tablets
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Metoprolol Succinate Extended-Release Tablets
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Lansoprazole Delayed-Release Capsules
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Lansoprazole Delayed-Release Capsules
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Famotodine Tablets
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Famotodine Tablets
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Famotodine Tablets
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Azithromycin Tablets
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Azithromycin Tablets
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Zolpidem Tartrate Tablets
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Lisinopril Tablets USP
CGMP Deviations: Firm did not adequately investigate customer complaints.
Class II · Moderate risk
Lisinopril Tablets USP
CGMP Deviations: Firm did not adequately investigate customer complaints.